Vardenafil Hydrochloride Tablet
Product Images NDC 71610-508

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 71610-508). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 20 mg (71610 0508 02)

Label for Vardenafil Hydrochloride 20 mg oral tablets, containing 2 tablets per package. The label includes storage instructions to keep between 20-25 degrees Celsius and in a light-resistant container. It lists the manufacturer as Rivopharm SA, Nanno, Switzerland, and the labeler as Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. The NDC number is 71610-508-02.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical structure of the active ingredient Vardenafil Hydrochloride, showing its molecular arrangement including hydrochloride and water molecules.*

FDA Label Image

Figure 1 (Vardenafil Figure 2)

A set of three line graphs showing mean maximal changes in systolic blood pressure, diastolic blood pressure, and heart rate over time relative to the timing of Vardenafil treatment before NTG administration. The x-axis for each graph is labeled with time intervals (24h, 8h, 4h, 1h), while the y-axes represent changes in units of mmHg for blood pressure and bpm for heart rate, with error bars indicating variability.*

FDA Label Image

Figure 2 (Vardenafil Figure 3)

A line graph showing mean change in mmHg over time (hours) for placebo and Vardenafil 5 mg under simultaneous and 6-hour separation dosing conditions. The y-axis indicates mean change in mmHg from -15 to 15, and the x-axis represents time from 0 to 6 hours. Multiple lines represent different groups with circle and triangle markers for placebo and Vardenafil, respectively.*

FDA Label Image

Figure 3 (Vardenafil Figure 4)

Line graph depicting mean change in mmHg over 6 hours, comparing placebo and vardenafil 5 mg under simultaneous and 6-hour separation conditions. The y-axis shows mean change in mmHg, and the x-axis shows time in hours, illustrating variations between treatments and timing.*

FDA Label Image

Figure 4 (Vardenafil Figure 5)

A line graph showing mean change in mmHg over time (hours) comparing placebo (stage 1 and 2) and Vardenafil 10 mg and 20 mg doses. The x-axis represents time from 0 to 6 hours, and the y-axis shows mean change ranging from -10 to 5 mmHg. Data markers indicate different groups with placebo data slightly above zero and Vardenafil groups showing a decrease in mmHg over time.*

FDA Label Image

Figure 5 (Vardenafil Figure 6)

A line graph depicting mean change in mmHg over time (hours) for four groups: Placebo Stage 1, Placebo Stage 2, Vardenafil 5 mg, and Vardenafil 10 mg. The x-axis represents time from 0 to 6 hours, and the y-axis shows mean change in mmHg from -10 to 10. The graph compares blood pressure changes for placebo and two doses of Vardenafil.*

FDA Label Image

Figure 6 (Vardenafil Figure 7)

A line graph titled 'TERAZOSIN' showing mean change in mmHg on the y-axis versus time in hours on the x-axis over a 6-hour period. The graph compares blood pressure changes under conditions with placebo, 10 mg Vardenafil, and 20 mg Vardenafil, administered either with 6-hour separation or simultaneously, using distinct line styles and markers for each group.*

FDA Label Image

Figure 7 (Vardenafil Figure 8)

A line graph titled 'TAMSULOSIN' showing mean change in mmHg on the y-axis and time in hours on the x-axis. The graph compares blood pressure changes over 6 hours for placebo and different doses of Vardenafil (10 mg and 20 mg) under simultaneous and 6-hour separation dosing conditions.*

FDA Label Image

Figure 8 (Vardenafil Figure 9)

Pharmacokinetic curve showing plasma concentration (µg/L) of Vardenafil Hydrochloride over time (hours). The graph illustrates plasma concentration peaking early and declining gradually to near zero over 24 hours, with error bars indicating variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.